Company Overview
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Why Investors Should Care
Revenue has grown at a 39.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $574.12M (-41.5% YoY); net profit $-1.24B.
- Trailing 12 Months Year-on-year growth — revenue +29.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 39.9%, profit CAGR -13.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.89% |
| 1 Year: | 29.30% |
Compounded Profit Growth
| 5 Years: | -13.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -57.62% |
| 6 Months: | -26.38% |
| 3 Months: | +1.87% |
| 1 Month: | -8.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 39.9% over 5 years.
CONS
- Earnings shrank at -13.6% CAGR over 5 years.
- Trading 63.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AAPG Ascentage Pharma Group Internat PHARMA | 17.44 | -7.39 | $1.63B | 0.00% | -50.94% | - | 39.89% | -13.59% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 209.71M | 221.98M | 980.65M | 574.12M |
| Cost of Revenue | - | 22.00M | 30.54M | 29.09M | 48.94M |
| Gross Profit | - | 187.71M | 191.44M | 951.57M | 525.18M |
| Operating Expenses | - | 1.04B | 1.06B | 1.32B | 1.72B |
| Operating Income | - | -849.81M | -872.64M | -369.73M | -1.20B |
| EBITDA | - | -771.47M | -743.61M | -237.63M | -1.10B |
| Interest Expense | - | 52.78M | 96.06M | 64.45M | 54.07M |
| Pretax Income | - | -887.17M | -932.86M | -395.25M | -1.24B |
| Tax Provision | - | -4.25M | -7.15M | 10.43M | 6.94M |
| Net Income | - | -882.92M | -925.64M | -405.43M | -1.24B |
| Diluted EPS | - | -13.40 | -13.12 | -5.36 | -13.96 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 2.83B | 2.50B | 2.62B | 3.96B |
| Current Assets | - | 1.64B | 1.34B | 1.47B | 2.94B |
| Cash & Equivalents | - | 1.48B | 1.07B | 1.24B | 2.46B |
| Inventory | - | 9.45M | 16.17M | 6.60M | 28.62M |
| Receivables | - | 54.36M | 145.89M | 83.14M | 252.94M |
| Total Liabilities | - | 2.42B | 2.43B | 2.34B | 2.63B |
| Current Liabilities | - | 881.15M | 934.17M | 1.17B | 1.64B |
| Long Term Debt | - | 1.27B | 1.17B | 868.64M | 742.33M |
| Total Debt | - | 1.79B | 1.80B | 1.67B | 1.98B |
| Total Equity | - | 408.66M | 60.42M | 264.19M | 1.32B |
| Shares Outstanding | - | 265.19M | 290.20M | 315.22M | 373.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -653.91M | -726.08M | -111.36M | -1.17B |
| Investing Cash Flow | - | -384.61M | 21.92M | -362.04M | -1.00B |
| Financing Cash Flow | - | 619.27M | 368.75M | 314.77M | 2.54B |
| Capital Expenditure | - | -236.96M | -56.84M | -24.29M | -27.57M |
| Free Cash Flow | - | -890.88M | -782.92M | -135.65M | -1.20B |
| Net Change in Cash | - | -419.26M | -335.40M | -158.62M | 365.92M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 89.5% | 86.2% | 97.0% | 91.5% |
| Operating Margin % | - | -405.2% | -393.1% | -37.7% | -208.6% |
| Net Margin % | - | -421.0% | -417.0% | -41.3% | -216.5% |
| ROE % | - | -216.1% | -1,532.1% | -153.5% | -93.8% |
| ROCE % | - | -43.6% | -55.7% | -25.5% | -51.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | 0.01% | 13.84K | $208.44K |
| 2 | Eversource Wealth Advisors, Llc | - | 24 | $361 |
| 3 | Caitong International Asset Management Co., Ltd | - | 1 | $15 |
| 4 | Blackrock Inc. | - | 6 | $90 |
| 5 | Morgan Stanley | - | 919 | $13.84K |
| 6 | UBS Group AG | - | 15 | $225 |
| 7 | Wells Fargo & Company | - | 200 | $3.01K |
| 8 | Royal Bank of Canada | - | 6 | $90 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AAPG
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discov…
ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary
Moby summary of ASCENTAGE PHARMA GROUP INTERNATIONAL's Q2 2026 earnings call
Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Group International (NASDAQ:AAPG) reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside Ch…
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business…
Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses
Half year earnings put Ascentage Pharma Group International (SEHK:6855) losses in focus Ascentage Pharma Group International (SEHK:6855) released half year earnings to June 30, 2026, reporting sales of CNY 302.21 million and a net loss of C…
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discove…
AAPG — Frequently Asked Questions
What is the current share price of Ascentage Pharma Group Internat (AAPG)?
As of 2026-09-19 21:16 PDT, Ascentage Pharma Group Internat (AAPG) trades at $17.44 on NasdaqGM. Its 52-week range is $16.23 to $47.90.
What is the market capitalisation of AAPG?
Ascentage Pharma Group Internat (AAPG) has a market capitalisation of $1.63B on NasdaqGM.
What is the P/E ratio of AAPG?
AAPG trades at a trailing price-to-earnings (P/E) ratio of -7.39. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 16.94.
Is AAPG a good stock to buy?
This page provides a data-driven analysis of Ascentage Pharma Group Internat (AAPG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.